Ocaxx.Ax
OCAXX.AX operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services, generating revenue primarily through its operations in this field.
Business. OCAXX.AX operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services, generating revenue primarily through its operations in this field.
Analyst recommendations
5 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
OCAXX.AX operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services, generating revenue primarily through its operations in this field.
The company's capital structure is characterized by a debt-to-equity ratio of 0.58, indicating a moderate level of leverage. Despite a negative operating income of -40,328,000 NZD, the company reported a net income of 30,415,000 NZD, suggesting effective cost management or non-operating income sources. The company's liquidity position is assessed as medium, with a cash and equivalents balance of 7,589,000 NZD, which is significantly lower than its long-term debt of 638,306,000 NZD.
In terms of profitability, the company's return on equity (ROE) is 2.76%, and its return on assets (ROA) is 1.03%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns from equity and assets.
The company's revenue is concentrated in a single segment, as no specific segments are disclosed, and there is no geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn.
The company's growth trajectory is uncertain, as there is no specific outlook provided for the current or next fiscal year. However, the company's operating cash flow of 110,277,000 NZD and free cash flow of 12,325,000 NZD suggest some capacity for reinvestment or debt reduction.
The company faces a medium liquidity risk, as its cash and equivalents are insufficient to cover its long-term debt. Additionally, the dilution risk could not be assessed due to missing basic and diluted share counts. The company's capital expenditure of -40,238,000 NZD indicates a reduction in capital spending, which could affect future growth.
Recent events and filings do not provide specific details, but the company's financial snapshot indicates a need for careful monitoring of its liquidity and debt management strategies.
- The company has a moderate level of leverage with a debt-to-equity ratio of 0.58.
- Despite a negative operating income, the company reported a net income, indicating effective cost management.
- The company's ROE and ROA are below the industry median, suggesting underperformance in generating returns.
- The company's liquidity position is medium, with cash and equivalents significantly lower than long-term debt.
- The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year.
- The company's capital expenditure has decreased, which could impact future growth.
- **margin_outlook_rationale**: The company's margin outlook is uncertain due to a negative operating income and a net income that is significantly lower than the operating loss.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,08 |
| Revenue | —no estimate | —no estimate | 380,3M NZD |
| Operating income | —no estimate | —no estimate | 87,7M NZD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- OCAXX.AX Market data — financials · 2026-05-28
- Oceania Healthcare Ltd Market data — analyst estimates · 2026-05-28